News

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who…
Read More...

H. Lundbeck A/S and Contera Pharma have announced a strategic research collaboration aimed at developing RNA-based medicines for serious neurological disorders with high unmet medical…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who…
Read More...

The Global Fund to Fight AIDS, Tuberculosis and Malaria has welcomed a new £6 million investment from GSK and its HIV specialist company ViiV Healthcare to strengthen community-led…
Read More...

Roche announced positive Phase III results from its evERA Breast Cancer study, showing that the investigational drug giredestrant, when combined with everolimus, significantly improved…
Read More...

Merck, through its U.S. and Canada healthcare division EMD Serono, has announced a landmark agreement with the Trump Administration to significantly expand access to in vitro…
Read More...

Tubulis, a German biotech company specializing in next-generation antibody-drug conjugates (ADCs), has secured €308 million (USD 361 million) in a major Series C financing round aimed…
Read More...

Novo Nordisk and Omeros Corporation have entered into a definitive agreement granting Novo Nordisk exclusive global rights to zaltenibart (formerly OMS906), a clinical-stage antibody…
Read More...

Adcytherix SAS, a French biopharmaceutical company developing next-generation antibody drug conjugates (ADCs), has closed a €105 million (US$122 million) Series A funding round — the…
Read More...

Minovia Therapeutics Ltd., a clinical-stage biotech company focused on mitochondrial disease therapies, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan…
Read More...

Viatris Inc., a global healthcare company, has announced the acquisition of Aculys Pharma, Inc., a clinical-stage biopharmaceutical firm focused on innovative neurological treatments.…
Read More...

Avantor, Inc., a global leader in life sciences and advanced technology products, has announced a strategic partnership with BlueWhale Bio, a commercial-stage company focused on…
Read More...

Johnson & Johnson has announced plans to separate its Orthopaedics division into a standalone company, DePuy Synthes, as part of a strategic move to sharpen its focus on high-growth…
Read More...

BioCryst Pharmaceuticals announced it will acquire Astria Therapeutics in a cash-and-stock deal valued at approximately $700 million, aiming to expand its portfolio of treatments for…
Read More...

Nabla Bio, a biotechnology company using generative AI to design novel therapeutics, announced a major expansion of its partnership with global pharmaceutical company Takeda. The new…
Read More...

Pfizer Inc. announced positive topline results from its Phase 3 HER2CLIMB-05 trial, marking a potential breakthrough in first-line treatment for patients with HER2-positive (HER2+)…
Read More...

Jacobio Pharma (1167.HK) announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd., has signed a Capital Increase and Equity Transfer Agreement with Oceanpine Capital and…
Read More...

Clinical-stage biotech company SystImmune has dosed the first patient in a global registrational Phase 2/3 trial for its experimental cancer therapy izalontamab brengitecan (iza-bren),…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for RINVOQ (upadacitinib), broadening its use in the treatment of moderately to severely…
Read More...

The U.S. Food and Drug Administration (FDA) has approved UZEDY (risperidone) as a once-monthly, long-acting injectable for the maintenance treatment of bipolar I disorder (BD-I) in…
Read More...